{"meshTags":["Child","Adenocarcinoma, Follicular","Combined Modality Therapy","Thyroid Neoplasms","Humans","Adenocarcinoma, Papillary","Thyroidectomy","Female","Pregnancy","Neoplasm Staging","Adult","Adenoma, Oxyphilic","Biopsy, Needle","Prognosis"],"meshMinor":["Child","Adenocarcinoma, Follicular","Combined Modality Therapy","Thyroid Neoplasms","Humans","Adenocarcinoma, Papillary","Thyroidectomy","Female","Pregnancy","Neoplasm Staging","Adult","Adenoma, Oxyphilic","Biopsy, Needle","Prognosis"],"organisms":["9606"],"publicationTypes":["Journal Article","Review"],"abstract":"Thyroid cancer will be diagnosed in more than 20,000 individuals in the United States in 2002. Approximately 16,000 of these patients will be women. During the same year, an estimated 1300 deaths from thyroid cancer are expected. The various types of thyroid cancer include papillary carcinoma, follicular carcinoma, Hurthle cell carcinoma, medullary carcinoma, anaplastic carcinoma, and thyroid lymphoma. Papillary, follicular, and Hurthle cell carcinoma are considered well-differentiated thyroid cancers and constitute the focus of this article.","title":"Well-differentiated carcinoma of the thyroid.","pubmedId":"12803010"}